KINTOR PHARMA-B (09939) released its interim results, reporting a net loss of 75.782 million yuan, a year-on-year decrease of 8.99%.

KINTOR PHARMA-B (09939) announced its interim results for the six months ending June 30, 2026, with revenue rising from 6 million yuan in the same period last year to 52 million yuan. The net loss was 75.782 million yuan, an 8.99% year-on-year decrease; the loss per share amounted to 0.15 yuan. The announcement stated that the revenue increase was mainly driven by the global sales of the new high-end cosmetics brand KOSHIN, spurred by live-streaming e-commerce (with its main ingredient KX-826 being one of the companys core products). The group continues to explore different methods to further promote the commercialization of its cosmetics on a global scale. The company intends to utilize the cash flow generated from its cosmetics sales business to fund the development and commercialization of its core products KX-826 and GT20029, along with other pipeline products. Additionally, the company will continue to adhere to its established business policies for its listed operations. The reduction in net loss was primarily due to decreased R&D costs, which were partially offset by increased sales and marketing expenses driven by higher marketing and promotional spending.